Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Receivables (2021 - 2025)

Historic Receivables for Tg Therapeutics (TGTX) over the last 5 years, with Q3 2025 value amounting to $265.4 million.

  • Tg Therapeutics' Receivables rose 12931.9% to $265.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.4 million, marking a year-over-year increase of 12931.9%. This contributed to the annual value of $152.7 million for FY2024, which is 16790.13% up from last year.
  • As of Q3 2025, Tg Therapeutics' Receivables stood at $265.4 million, which was up 12931.9% from $231.5 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Receivables high stood at $265.4 million for Q3 2025, and its period low was $88000.0 during Q2 2022.
  • Its 5-year average for Receivables is $73.2 million, with a median of $46.1 million in 2023.
  • In the last 5 years, Tg Therapeutics' Receivables crashed by 9054.78% in 2022 and then surged by 1976818.18% in 2023.
  • Quarter analysis of 5 years shows Tg Therapeutics' Receivables stood at $1.4 million in 2021, then plummeted by 93.66% to $88000.0 in 2022, then skyrocketed by 64664.77% to $57.0 million in 2023, then skyrocketed by 167.9% to $152.7 million in 2024, then skyrocketed by 73.81% to $265.4 million in 2025.
  • Its Receivables was $265.4 million in Q3 2025, compared to $231.5 million in Q2 2025 and $190.1 million in Q1 2025.